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S314 Poster Session IIWhen used as therapy for hematopoietic malignances, allogeneic
bone marrow transplantation (BMT) relies on the graft-versus leu-
kemia (GVL) effect to eradicate residual tumor cells through
immunologic mechanisms. However, graft-versus-host-disease
(GVHD) is a potentially lethal complication of allogeneic BMT.
Thus, inhibition of GVHD, while preserving GVL and protective
responses against infectious agents, can enhance the therapeutic
potential of BMT. GVHD is initiated by alloreactive donor T cells
that recognize mismatched major (MHC) and/or minor (MiHA)
histocompatibility antigens and cause severe damage to hematopoi-
etic and epithelial tissues. Protein kinase C theta (PKCq) is a key
regulator of T cell-receptor signaling. We show here that T cell
responses triggered by Listeria or following administration of anti-
gen plus microbial adjuvant are relatively well preserved in the ab-
sence of PKCq. In contrast, we demonstrate an essential
requirement for PKCq in alloreactivity and GVHD induction. Fur-
thermore, absence of PKCq raises the threshold for T cell activa-
tion, which selectively impacts alloresponses. Most importantly,
PKCq
-/- T cells retain both the ability to respond to virus infection
and induce GVL post BMT. These findings validate PKCq as
a potentially unique therapeutic target that is required for
GVHD induction but not for GVL or protective responses to
infectious agents.425
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Advances in clinical trials for treatment of chronic GVHD have
been hampered by slow accrual of patients (pts) and by inconsistency
and limitation of historical systems for grading used prior to the 2005
NIH consensus criteria for diagnosis and classification of chronic
GVHD (Filipovich AH et al BBMT 2005;11:945-956). In an effort
to foster collaboration and expand the network for future clinical tri-
als in chronic GVHD, a Brazil-Seattle consortium was established in
2008 to conduct chronicGVHDstudies in Brazil. The Brazil-Seattle
chronic GVHD consortium included 15 multidisciplinary partici-
pants (i.e., hematopoietic cell transplant (HCT) physicians, derma-
tologist, dentist, psychiatrist, psychologist, physiotherapist and one
data manager) from 5 Brazilian institutions and two experts in
chronic GVHD from Seattle. The consortium held monthly tele-
conferences and met at least twice yearly during national and inter-
national HCT and Hematology meetings in Brazil and USA. After
training and translation of theNIH consensus criteria tools into Por-
tuguese, the group initiated a feasibility study using theNIH consen-
sus criteria after approval by each of the 5 participating centers’
institutional review boards. So far, 34 pts with NIH chronic
GVHD after allogeneic HCT in Brazil have been enrolled between
June 2006 and May 2009 and prospectively followed. Of the 34 pts
with NIH chronic GVHD, 26 (76%) met the overlap syndrome sub-
category and 8 (24%) the classic subcategory. The overall severity of
NIH chronic GVHDwas moderate in 21 pts (62%) and severe in 13
pts (38%). The median time from HCT to onset of NIH chronic
GVHD overlap syndrome subcategory was 5.9 months (2.5-10) and
from transplant to NIH chronic GVHD classic subcategory was 7.3
months (3.0-16). At a median follow up of 16.5 months, the overall
survival was 70%. At least 5 pts were enrolled from each center. In
conclusion we demonstrate the feasibility of the NIH consensus cri-
teria for the diagnosis and scoring of chronicGVHD in a prospective
Brazilian multicenter study and, more importantly, in establishing
a collaborative HCT network in Brazil that offers new opportunities
for future intervention, validation, and biomarkers clinical trials in
chronic GVHD.426
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Introduction:Graft-versus-host disease (GVHD) is the most com-
mon complication of allogeneic hematopoietic cell transplantation
(alloHCT) and may affect the transplant outcome. Its incidence is
higher when the preparative regimen used is a non-myeloablative
and the stem cell’s source is peripheral blood after mobilization.
Objective: To demonstrate the 10 years incidence of GVHD in 2
Mexican transplant centers using peripheral hematopoietic stem
cell transplantation (PHSCT) in related donors after non-myeloa-
blative conditioning.
Patients andmethods:Three hundred and fifty six patients with he-
matological and non-hematological malignancies that underwent
PHSCT after non-myeloablative conditioning between October
1998 and November 2008 were included. The age ranged between
1 and 71 years (median of 29). Two hundred and nineteen patients
were men and 137 women. They received cyclosporine 4 mg/kg
per day and intramuscular methotrexate 5 mg/m2 in days +1, +3,
+5 and +11 for GVHD prophylaxis.
Results: Three hundred and fourteen (88%) patients were suc-
cessfully engrafted. One hundred and fifty six patients (49%) de-
veloped acute and/or chronic GVHD. Of this last number of
patients, 68 (44%) developed acute GVHD, 44 (28%) developed
chronic GVHD, and 44 (28%) developed both. Twenty three
percent (26) of the patients who developed acute GVHD were
grade III or IV, and 35% (31) of chronic GVHD patients pre-
sented in the extensive way. GVHD was the cause of dead in 33
patients (12%), even when immunosuppressive therapy (high
dose steroids and rituximab) was used. Last death was 24 months
ago; subsequently, alemtuzumab was included in GVHD
treatment.
Conclusion: The incidence of acute and chronic GVHD in our pa-
tients is lower than the reported in the literature, even though the
source of hematopoietic stem cells was peripheral blood. The mor-
tality rate has decreased due to the introduction of new are more ag-
gressive immunosuppressive agents like alemtuzumab.427
MOBILIZING CELLS WITH A TOLEROGENIC PHENOTYPE USING PEGY-
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Granulocyte-macrophage colony stimulating factor (GM-CSF)
is a growth factor regulating proliferation and differentiation of
hematopoietic stem and progenitor cells. Murine GM-CSF
(mGM-CSF) has a very short half-life and pegylation of mGM-
CSF (peg-mGM-CSF) has been shown to prolong its half-life.
Based on our clinical observations that patients transplanted
with stem cell products mobilized by GM-CSF have a lower inci-
dence of acute GvHD, we hypothesized that peg-mGM-CSF may
be protective of acute GvHD in a MHC mismatched murine
model.
We have shown that C57/Bl6 mice treated with peg-mGM-
CSF led to increased CFU-C by 26.5 fold compared to PBS
treated mice (n5 6, 95% CI5 10.25-42.73). (ASH 2009) In
addition, we observed that peg-mGM-CSF increased
CD4 + FoxP3 + Tregs in both blood and spleen by 2 fold.
(p\0.05) (ASH 2009) This effect was sustained out to 4 days af-
ter the last dose of peg-mGM-CSF. Importantly, the function of
these peg-mGM-CSF Tregs, as measured in a MLR was found to
be equivalent to Tregs from PBS treated control mice (n5 3,
p5 0.27) (ASH 2009)
To assess the in vivo impact of peg-mGM-CSF on graft versus
host disease, we used the C57/Bl6/ Balb/c acute GvHD model.
Poster Session II S315We hypothesized that treatment of recipients peri-transplant with
peg-mGM-CSF may be protective of GvHD and improve survival
by increasing recipient Tregs. Balb/c mice (n5 5/group) were
treated with peg-mGM-CSF or PBS for 4 days prior to transplanta-
tion using myeloablative conditioning and transfer of B6 splenic
T-cells and bonemarrow. This was followed by continued treatment
with either PBS or peg-mGM-CSF for the first week after transplant.
There was a trend toward worse survival in the peg-mGM-CSF
treated recipients. (Log-rank (mantel-cox) test, p5 0.085) We next
asked if treatment of T-cell donors might abrogate GvHD. B6 do-
nors were treated with G-CSF, peg-mGM-CSF or PBS for 4 days,
on the fifth day splenocytes were isolated and pan-T-cell selected us-
ing an AutoMACS column. An equivalent dose of CD3 +T-cells
along with congenic bone marrow was administered to recipient
Balb/c mice (n5 4-5/group) that had undergone myeloblative con-
ditioning. Mice receiving GM and G treated donor T-cells had an
improved survival compared to PBS alone (PBS vs. G p5 0.0314,
PBS vs. GM p5 0.0467 (Log rank (Mantel cox) test)) but displayed
similar GvHD scores. This effect may be explained by an increase in
Tregs delivered in the G and GM group. Further studies will seek to
validate these results.428
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Syngeneic graft-versus-host disease (SGVHD) was first described
as aGVHD-like syndrome that developed following syngeneic BMT
and cyclosporine A (CsA) treatment. SGVHD is induced by recon-
stituting lethally irradiated mice with syngeneic bone marrow cells
followed by a 21 day treatment with the immunosuppressive agent
CsA. Clinical symptoms of the disease appear 2 to 3 weeks following
cessation of CsA therapy and disease-associated inflammation occurs
primarily in the colon and liver. CD4+ T cells have been shown to
play an important role in the inflammatory response observed in
the gut of SGVHDmice. Time course studies revealed a significant
increase in the migration of CD4+ T cells into the colon during CsA
therapy (as early as day 14 post-BMT). Significantly elevated levels of
proinflammatory cytokines, chemokines and cellular adhesion mol-
ecules were observed in the colonic tissue of CsA treated animals
compared to BMT controls. Homing studies revealed that a labeled
CD4+ T cell line, generated from SGVHD mice, migrated to
a greater extent into the gut of CsA treated mice at day 21 post-
BMT compared to control animals. This study demonstrates that
during the 21 days of immunosuppressive therapy, functional mech-
anisms are in place that result in increased homing of CD4+ T
effector cells to the colons of CsA-treated mice.429
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Rare causes of abdominal pain may be overlooked in allogeneic
transplant recipients with recurrent episodes of abdominal pain.
We describe a 19 year-old female, who received a matched unrelated
donor peripheral blood stem cell transplant for acute myeloid leuke-
mia-M4; presenting with recurrent abdominal pain. The transplant
conditioning regimen was fludarabine (125 mg/m2) and melphalan
(140 mg/m2) and graft versus host disease (GvHD) prophylaxis
was tacrolimus and methotrexate. The post transplant course was
complicated by acute and chronic GvHD of the GI tract and skin,
treated with calcineurin inhibitors, glucocorticoids, mycophenolate
mofetil, sirolimus, azathioprine, extracorporeal photopheresis andnarrow beam ultraviolet B (UVB). 18 months after transplantation,
she presented with recurrent crises of abdominal pain. Endoscopic
biopsies were negative for GI GvHD. CT scan and ultrasound of
the abdomen suggested a complex 6  9 cm adnexal cyst arising
from the left side. Diagnostic laparoscopy findings were inconsistent
with a cyst. A subsequent CT of the pelvis suggested a hematocolpos.
Vaginal exploration identified a transverse vaginal septum occluding
menstrual flow. Transection was performed and a copious amount of
blood was drained with relief of symptoms. Patient presented two
months after surgery with recurrent pain and ultrasonogram demon-
strated hematocolpos requiring resection of the vaginal scar tissue to
alleviate the obstruction. Patient’s post operative course was compli-
cated with tubo-ovarian abscess resulting with rupture and septic
shock; she underwent laparoscopic right salpingo-oophorectomy.
The patient improved and was released from the hospital 2 weeks
later. Biopsy of the vaginal obstruction showed a segment superfi-
cially ulcerated endocervical-type columnar mucosa and portions
of fibromuscular tissue consistent with vaginal GvHD. In summary,
scarring from unrecognized vaginal GvHD led to retention of men-
ses and chronic abdominal pain. She is now using vaginal dilators
with topical steroids to prevent further recurrence and clinically
doing well. This case is presented to highlight awareness of this
rare complication.430
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Although severe nephrotic syndrome (NS) has been found as
a major symptom of cGVHD in murine models, the effect of
GVHD on human kidney has not been studied extensively. We de-
scribe a case of NS in 16 years old female patient that was submit-
ted to an identical sibling allo BMHSCT for CML in 1st CP. The
conditioning was the BuCy regime. She received 3,8  108 mono-
nuclear cells/kg. The GVHD prophylaxis was CSA/MTX. On
D + 180, she was Phi and BCR-ABL negative and free from immu-
nosupression without any symptons of GVHD. Five years after
transplantation, she presented a cytogenetic relapse with 20% of
Phi+ cells. She was treated with two DLI infusions (1.5  106
CD3+ cells/kg and 1107 CD3+ cells/kg) and she became BCR-
ABL negative. Until two years after the second DLI she never pre-
sented any signs or symptons of GVHD. After that, she started
with intermittent urticaria and edema on the face that progress
to anasarca. The clinical and laboratory investigation revealed pro-
teinuria 2 to 8 g/24 h, hypoalbuminemia (2,3 mg/dl) and hematu-
ria. Phi chromosome, BCR-ABL, serology for virus, syphilis and
colagenosis antibodies were all negative. A kidney biopsy revealed
findings of early membranous glomerulonephritis with mild mesan-
gial proliferative glomerulopathy. The IMF confirmed granular
immune deposition for IgG along the capillary loops. She was ini-
tialy treated with prednisone 1 mg/kg plus a loop diuretic and an
angiotensin II receptor blocker. Secondary to steroid resistance, cy-
clophosphamide 1 g/m2 plus rituximab 325 mg/m2 for two times,
in 15 days interval, was administered. Six weeks after the second
cycle of Cy/Rituximab the intermittent urticaria and 8 g/24 h pro-
teinuria were still present. Thus, the patient started CSA 5 mg/kg.
After six months of CSA, the urticaria and proteinuria (170 mg/
24 h) disappeared completely, and albumin reaches 3.6 mg/dl.
Now, she is in a tapering regimen for CSA. NS following HSCT
is a rare complication. It is mainly related to membranous nephrop-
athy and less frequently to minimal change disease, focal segmental
glomerulonephritis, diffuse proliferative glomerulonephritis or IgA
nephropathy. Other renal complications of HSCT include drug
and radiation toxicity and thrombotic microangiopathy that need
to be ruled out in the differential diagnosis. In conclusion: the lit-
erature supports the existence of renal GVHD. However, further
investigations are warrant since the pathophysiology is unclear
and there is no treatment established.
